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Tla is a  region on the  17th chromosome located telomeric to the D  region of H-2 
(1). This segment contains two subregions, Qa2 and Tla. The Tla subregion has two 
loci, Tla and Qa-1, that control the expression of TL and Qa-l, respectively. TL is an 
antigen that is expressed on thymocytes and leukemias of T  cell origin, whereas Qa- 
1 has a  more widespread tissue distribution that includes thymocytes, peripheral T 
and B cells, and T  and B cell lymphoblasts (1-3).  In functional assays, it has been 
demonstrated that Qa-1 is expressed on two subpopulations ofT lymphocytes involved 
in feedback suppression (4, 5). 
The Qa2 subregion controls the expression of four antigenic specificities, Qa-2, Qa- 
3,  Qa-4,  and  Qa-5,  each  of which  is  principally  detected  on  the  membrane  of 
lymphoid cells and/or their precursors (1, 6, 7). The Qa-2 antigen has a wide tissue 
distribution, including most normal T  lymphocytes, a portion of thymocytes, T  and 
B  cell  lymphoblasts, multipotential stem cells, progenitors of granulocytes/macro- 
phages, and some natural killer (NK) 1 cells (6, 8-11). This molecule has been analyzed 
structurally and consists of a  40,000  mol wt heavy chain noncovalently associated 
with beta 2-microglobulin, making it similar in structure to class I H-2 antigens (12, 
13). Further, peptide map analysis of the heavy chain indicates considerable structural 
homology between Qa-2 and H-2 (14). 
Currently, the function of the genes in the Qa2 subregion is not understood. Further, 
it is not known whether the Qa2 subregion contains several nonpolymorphic loci that 
encode for individual Qa antigens, or alternatively, whether this region contains one 
gene  with  several  alleles.  To  approach  this  question,  we  generated  cytotoxic  T 
lymphocytes (CTL) against antigens controlled by the Qa2 subregion in an attempt 
to (a)  determine whether Qa-2 functions in a  manner similar to that of H-2 class I 
antigens and (b) to charactertize the genetic organization of this region. 
We  provide  evidence  that  CTL  can  be  generated  against  two  different  Qa2 
subregion-controlled antigens. One target antigen is (a) controlled by the Qa-2 gene, 
(b)  recognized by H-2-unrestricted effector cells, (c)  detected with monoclonal anti- 
* Supported by  grants AI13111,  AIl1851,  CA27824,  and  AI12603 from the National  Institutes of 
Health. 
i Abbreviations used in this paper:  Con A, concanavalin A; CTL, cytotoxic T  lymphocytes; NK, natural 
killer; NMS, normal mouse serum. 
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Qa-2 antibody, and  (d)  is not the product of a  polymorphic locus.  A second target 
antigen is also described and is associated with the expression of the Qa-5 specificity. 
Materials and Methods 
Mice.  All mice were obtained from our breeding colonies at The University of Texas Health 
Science Center at Dallas, Dallas, TX, and the New York State Department of Health, or were 
purchased from The Jackson Laboratory,  Bar Harbor, ME. The B10.W (wild) strains of mice 
were kindly provided by Dr. Jan Klein, Max Planck Institute, Tubingen, Germany. The H-2 
and  Qa/Tla  genotypes of the strains used are listed in Table I. 
Generation  and Assay for  CTL  Activity.  These methods  have been described previously (15). 
Briefly, animals were primed  in vivo with 30 ×  l0  s Qa-2-incompatible spleen cells. After an 
interval  of 3  wk  to  6  mo,  the  spleens  from  the  primed  mice  were  removed,  a  single  cell 
suspension made, and the cells cultured with irradiated stimulator spleen cells in vitro. After 5 
d, the effector cells generated were tested for c ftotoxic activity against ~lCr-labeled concanavalin 
A  (Con A) lymphoblast target cells. Net release of isotope represents percent release of isotope 
from  target  cells in the presence of immune cells minus  the percent  release of isotope  from 
target cells in the presence of nonimmune cells (control release). Control release ranged from 15 
to 30%, and the standard  error from triplicate wells did not exceed 10%. 
TABLE  I 
H-2  and Qa-l /  Tla Genotypes,  Qa2 Subregion  Phenotypes 
Q~ 
Strain  H-2  Tla 
B6 
B6.K1 
B6.K2 
B10 
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BALB/cJ 
BALB/cByJ 
B10.D2 
DBA/2 
DBA/1 
SWR 
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B10.M 
B10.BR 
A.SW 
A.TL 
BI0.S 
BI0.STC77 
B 10.KPB 128 
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Data taken from references  1, 21, 33, and this publication. 
* Indicates weak reaction with serological typing reagent.  Cells from all Qa-5 b 
strains  show reduced reactivity with anti-Qa-4 (7). 
~: Not typed. 
§ See Table IV for explanation. J.  FORMAN, J. TRIAL, S.  TONKONOGY, AND L.  FLAHERTY  751 
CTL Competition Assay.  This methodology has been described previously (16). Briefly,  108 
effector and 104 labeled target cells were added to individual wells in microtiter plates together 
with unlabeled inhibitor cells. The number of unlabeled cells ranged from l0  s to 1.5 X 108 cells 
per well. 
Blocking of CTL Activity with Antibodies.  Alloantisera and monoclonal antibodies or normal 
mouse sera (NMS)  and myeloma proteins at varying concentrations were added to individual 
wells of microtiter plates together with target cells. After a 45-min in6ubation at 37°C, effeetor 
cells were added, and the cultures were incubated for an additional 4 h before harvesting. 
Antisera.  Anti-H-2  b  and  anti-H-2  d  sera  were  produced  by  multiple  inoculations  of 
C57BL/10 spleen cells into B 10.D2 recipients  and vice-versa. Anti-TL sera were produced by 
immunization of (B6 X A.CA)FI mice with B6.Tla  a ceils (anti-TL 5, 6) and (B6 X A.Tlab)F1 
mice  with  ASL-1  tumor  (H-2  a)  cells  (anti-TL  1,2,3,5,6).  Anti-Qa  sera  was  produced  by 
immunizing B6.K1  mice with B6 lymphoid cells, as described previously (6). This sera has 
known activity against Qa-2 and Qa-3 and can potentially recognize Qa-4 and Qa-5. Anti-Qa- 
2 monoclonal antibody was produced by somatic cell hybridization according to the method of 
Galfre et al.  (17). This antibody has a cytotoxie titer of >10  s and was defined as anti-Qa-2 
because it killed a higher percentage of peripheral T cells than monoclonal anti-Qa-4. Anti-Qa- 
5 monoclonal antibody has been described previously (7) and has a cytotoxic titer of > 150. 
Results 
The CTL used in this study were generated against antigens controlled by the Qa2 
subregion.  The strain  distribution  of the  antigens  controlled  by this  subregion  are 
listed in Table I. Because there are no strains that dissociate Qa-2 and Qa-4, in this 
section  we have tentatively designated  these  two specificities as  defining  the  same 
antigen,  Qa-2  (see Discussion).  However, it should  be kept in  mind  that  these two 
specificities could each be controlled by a separate gene. 
The Ability of Qa  Congenic Strains to Generate CTL Activity.  We previously demon- 
strated  (15)  that  BALB/cByJ  mice immunized  in  vivo and  boosted  in  vitro with 
BALB/cJ spleen cells generate anti-Qa-2 CTL activity. Because these two sublines of 
BALB/e  mice  have  been  separated  for >30  yr  (18),  it  is  possible  that  there  are 
extensive genetic differences, in addition to that at the Qa2 subregion, between these 
strains. Therefore, we used the recently developed congenic strains, B6.K1 and B6.K2, 
which differ at the Qa2 subregion but not Qa-1 or Tla, to generate anti-Qa CTL (6). 
When B6.K1  mice were primed in vivo with B6.K2 spleen cells and then boosted 
in vitro with B6.K2 stimulator cells, no CTL activity was generated (data not shown). 
Because we have previously shown  in  the Qa-1  CTL system that  B6.TIa  a mice are 
nonresponders  when  primed with  Qa-1/Tla congenic spleen  cells,  but  can  be con- 
verted  to  responders  by  priming  in  vivo  with  Qa-1/Tla  disparate  noncongenic 
splenocytes (19), we decided to test the same approach in these experiments. Accord- 
ingly, B6.K1 mice were primed with A.BY cells in vivo. A.BY mice share the H-2 and 
Qa-1/Tla complex with B6.K1  but differ with respect to Qa-2, Qa-3, and Qa-5  (see 
Table I) as well as at multiple minor H  antigens. As demonstrated in Table II, B6.K1 
animals primed in vivo and boosted in vitro with A.BY cells generate anti-Qa CTL 
activity (lines  1-5).  It is not  necessary to use A.BY stimulator cells for the in vitro 
cultures,  as B6.K2 stimulator cells also generate anti-Qa CTL activity (lines 6-10). 
Further,  B6.K2 stimulator cells generate as much CTL activity from B6.K1  spleen 
cell  CTL  precursors  as  do  A.BY  stimulator  cells  when  tested  against  B6.K2  and 
BALB/cJ but not against A.BY target cells (lines  1, 3, 4, 6, 8, 9). In the case of the 
latter  target  cells,  the  B6.K1  anti-A.BY  CTL also  recognize  minor H  antigens  on 
A.BY but not B6.K2 or BALB/cJ target cells (data not shown).  Further,  an alloan- 752  CYTOTOXIC T  CELLS AGAINST Qa-2 
TABLE II 
Ability of Qa2 Congenic Strains to Generate Anti-Qa CTL Responses 
Line  Responder  cells  Target cells 
Net 5aCr release,  Stimulator cells  E:T 
In vivo  In vitro  100  50  10 
1  B6.KI  A.BY*  A.BY  A.BY  30  25  12 
2  B6.K1  2  1  1 
3  B6.K2  16  11  5 
4  BALB/cJ  11  8  3 
5  BALB/cByJ  3  2  2 
6  B6.K2  A.BY  21  14  4 
7  B6.K1  1  0  0 
8  B6.K2  20  18  4 
9  BALB/cJ  13  9  2 
10  BALB/cByJ  4  1  1 
11  B6.K1 9  B6.K2 ~  B6.K2  d  BALB/cJ  23  14  4 
12  BALB/cByJ  4  5  6 
t3  B6.K2  20  14  8 
* B6.K1 animals were primed in vivo with sex-matched  A.BY spleen cells before in vitro culture. 
:~ B6.K1 9 animals were primed in vivo with d B6.K2 spleen cells before in vitro culture. Target cells were 
from 9 animals. 
tigenic difference at  H-Y also allows for successful priming of B6.K1  anti-Qa CTL 
(lines  11-13). 
Therefore, immunization of B6 congenic pairs of mice differing at the Qa2 subregion 
(above data)  or Qa-1  (19)  does not produce anti-Qa-2-5 or anti-Qa-1 b CTL, respec- 
tively.  However, priming such  mice in  vivo with  noncongenic  cells  followed by in 
vitro  stimulation  with  Qa  congenic  cells  permits  specific  cytotoxic  activity  to  be 
generated. In this study, we refer to anti-Qa2 subregion effector cells as B6.K1  anti- 
A.BY/B6.K2, to reflect the immunizations received. The role of"helper" determinants 
on  noncongenic  cells that  allow  for in  vivo priming of CTL.P  has been  addressed 
elsewhere (20). 
We previously reported  (15)  that BALB/cJ mice immunized against BALB/cByJ 
cells did not produce CTL that recognized a Qa-2- antigen. Similar results have been 
obtained  using A.BY  (Qa-2  +,  3 +,  5 +)  animals primed in  vivo and  boosted  in  vitro 
with  (non-Qa congenic)  B6.K1  (Qa-2-, 3-, 5-) spleen cells. No anti-Qa activity was 
generated, as determined by testing against BALB/cByJ (Qa-2-, 3-, 5-)  target cells 
(data not shown). Therefore, consistent with current  serologic data, strains that are 
Qa-2-, 3-, 5- do not express a Qa2 subregion-controlled CTL antigen. 
The Qa-3 Specificity Is Not Recognized by Anti-Qa CTL.  Our prior data (15)  indicated 
that BALB/cByJ (2-, 3-, 5-) anti-BALB/cJ (2 +, 3 +, 5-) effector cells were able to lyse 
DBA/1  (Qa-2  +,  3-,  5-)  target  cells,  demonstrating  that  Qa-2  is  a  target  antigen. 
However, that data did not exclude the possibility that Qa-3 could also be recognized 
by anti-Qa CTL.  To address  this  issue,  B6.K1  animals were sensitized  against  Qa 
antigens by priming with A.BY spleen cells in vivo, followed by boosting with B6.K2 
in vitro and tested for cytolytie activity against BALB/cJ targets, which express Qa- 
2,3. The data presented in Fig.  1 show that these effector cells cause lysis of BALB/cJ 
targets, as expected (net release at  100:1  ratio is 42%). To determine whether Qa-3 is 
a  target antigen  recognized by these effector cells, we asked whether DBA/1  (Qa-2) J.  FORMAN,  J.  TRIAL,  S.  TONKONOGY,  AND  L.  FLAHERTY  753 
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F1o.  1.  Qa-3 is not a target antigen for anti-Qa CTL. B6.KI anti-A.BY/B6.K2 effector cells were 
tested for their cytotoxic .activity  against BALB/cJ  (top panel) or DBA/I  (bottom panel)  target 
cells in the presence of unlabeled inhibitor cells from B6.K1  (*), BALB/cJ (O), and DBA/1 (+). Net 
release in the absence of inhibitor cells was 42% for BALB/cJ targets and 45% for DBA/1 targets. 
net release in presence of inhibitor cells 
percent inhibition ofCML =  1  X  100. 
net release in absence of inhibitor cells 
cold target  inhibitor cells were less effective than BALB/cJ  (Qa-2,3)  inhibitors in 
blocking CTL activity. The data presented in Fig.  1 (top panel)  demonstrate that 
both inhibitor cells block CTL activity to the same extent. As a control, we also show 
that both DBA/1 and BALB/cJ inhibitor cells equally block cytolytic activity against 
DBA/1 targets (Fig. 1, bottom panel). 754  CYTOTOXIC T CELLS AGAINST Qa-2 
Therefore, these data demonstrate that CTL are not generated against Qa-3; rather, 
CTL activity detected by B6.KI  anti-A.BY/B6.K2 effector cells  is directed against 
either Qa-2 or both Qa-2 and Qa-5. 
Qa-5 Is Associated with a Target Antigen Recognized by Anti-Qa CTL.  In testing whether 
Qa-3 was a target antigen for B6.K1 anti-A.BY/B6.K2 effector cells, we noted when 
using B6.K2 rather than BALB/cJ cells as targets that inhibitor cells from B10.D2 
mice (Qa-2,3) unexpectedly blocked only part of the CTL activity, similar to DBA/1 
cells (Fig. 2 A). When DBA/1 cells were used as targets, all three inhibitor cells (DBA/ 
1,  B6.K2,  and  B10.D2)  blocked  CTL  activity to  an  equivalent  extent  (data  not 
shown). Further testing using a larger panel of cells (Fig.  2 B) revealed two patterns 
of blocking: one complete, using inhibitor cells  from B6 and B6.K2, and the other 
partial, using inhibitor cells from B10.D2, A/Boy, A/J, DBA/2, and A.TL. Because 
the latter cells were only able to partially block CTL activity, this suggested that they 
may not express a specificity being detected by the effector cells. Examination of the 
Qa antigen distribution on the strains used in these experiments (Table I) indicates 
that strains unable to completely block lack the Qa-5 specificity. 
Although the above data suggest that one of the specificities that CTL recognize is 
associated with Qa-5 expression, other explanations are possible. For example, B6.K1 
and B6.K2 may differ at a minor H antigen so that CTL activity is generated against 
this specificity, which is restricted by//-2  b. Because only H-2  b cells express Qa-5 (see 
Table  I),  these would be  the only cells expected  to completely block in  the CTL 
competition assay. We rule out this possibility because the cyt.otoxic activity generated 
is completely blocked by anti-Qa-2 subregion sera and not anti-H-2 sera (see following 
section). In addition, it is unlikely that this postulated minor H  antigen is expressed 
on cells that have a  different background with respect to C57BL/6 mice, viz., A.BY 
and C3H.SW, because these cells completely block CTL activity in the competition 
assay (data not shown). 
A second possible explanation for the failure of inhibitor cells from certain strains 
to completely block CTL activity in the competition assay is that these cells express 
a relatively low amount of Qa-2 on Con A-stimulated lymphoblasts. To address this 
issue,  we generated B6.K1 effector cells sensitized to Qa-2 but not Qa-5 and tested 
them in the CTL competition assay. These effector cells were produced by priming 
B6.K1 animals with A.BY cells in vivo, followed by boosting with BALB/cJ (Qa-5-) 
cells in vitro. The data in Table III demonstrate that B6.K1 animals primed in vivo 
with A.BY cells and boosted in vitro with B6.K2 cells generate anti-Qa CTL activity, 
as expected. Further, the same primed cells boosted with BALB/cJ stimulator cells 
also display anti-Qa CTL activity, although to a  lesser extent, which may be due to 
the anti-H-2 response elicited concomitantly. IfQa-2 is expressed in greater quantities 
on H-2  b (Qa-5 +) Con A lymphoblasts, then boosting the B6.K1 effector cells with Qa- 
5- stimulators (BALB/cJ) should produce the same pattern of inhibition in the CTL 
competition assay as seen  in Fig.  2.  However, this was not observed.  Accordingly, 
B6.K1 mice primed in vivo with A.BY cells and boosted with BALB/cJ stimulators 
have their CTL activity blocked by Qa-5 + and Qa-5- inhibitor cells to an equivalent 
extent (Fig.  3 A), whereas the same responder cells boosted in vitro with B6.K2 cells 
have only part of their CTL activity blocked by BALB/cJ (Qa-5-)  inhibitors (Fig. 
3 B).  Thus,  the  presence  of Qa-5  (or  Qa-5  itself)  is  associated  with  a  specificity 
recognized by anti-Qa CTL. 755 
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F'O.  2.  Qa-5 is  associated  with a target  antigen for  anti-Qa CTL.  B6.KI anti-A.BY/B6.K2 effector 
cells were tested for their cytotoxic activity against B6.K2  target cells in the presence of unlabeled 
inhibitor cells from B6.K1  (V), DBA/1 (X), B6.K2  (*), B10D2 (C)), BI0.BR (+), B6 (&), DBA/2 
('),  A/J  (t),  and  A/Boy (I).  Net  release  in  the  absence  of inhibitor cells  was  31%  for  the 
experiment presented in panel a and 25% for the experiment presented in panel b. 
The  Qa-2  CTL  Antigen Is  on  the  Same Molecule as  the  Serologically Defined Qa-2 
Determinant.  The previous data indicate that CTL can be generated  by cross-immu- 
nizing Qa-ineompatible strains and that the specificity of the effector cells is for Qa- 
2  and  Qa-5,  as  defined  by  serological  typing  of target  cells.  However,  the  target 
antigens could either be encoded for by genes  that control the serologically defined 
Qa molecules, or alternatively,  they could be controlled by closely linked genes that 756  CYTOTOX1C T  CELLS AGAINST Qa-2 
TABLE III 
Generatwn of Anti-Qa CTL Activity in B6.KI Mice Using Qa-5- Stimulator Cells 
Cells  Net release, E:T 
Responders  Stimulators  Targets  100  50  10 
B6.K1 primed with A.BY  B6.K2 
BALB/cJ 
BALB/cJ  47  44  25 
BALB/cByJ  15  11  5 
B6.K2  53  50  32 
B6.K1  7  7  5 
BALB/cJ  41  38  18 
B6.K2  22  18  9 
B6.K1  0  3  4 
B6.K1 animals were primed in vivo  with A.BY spleen cells, followed  by boosting in vitro with either B6.K2 
(Qa-5  +) or BALB/cJ (Qa-5-) stimulator cells. 
express  the  same  positive  alleles  in  the  laboratory  strains  that  we  have  tested. 
Therefore,  to  determine  whether  the  same  locus  controls  both  Qa-2  CTL  and 
serological determinants, we used two different approaches. 
The first was to type seven B10.W  (wild)  strains for the presence of serologically 
defined Qa-2, using immune sera, and Qa-2 CTL determinants,  using BALB/cByJ 
anti-BALB/cJ effector cells. B 10.W mice have their H-2 haplotype and Qa2 subregion 
derived from individual wild mouse donors (21). Therefore, if there are two separate 
genes for Qa-2, one defined by serology and the other by CTL, then recombination 
would likely occur in the wild and allow us to detect a discordance between these two 
antigens. The data in Table.IV demonstrate that of the seven B10.W strains tested, 
five expressed  the  Qa-2  determinant  detected  by  CTL,  whereas  two  strains  were 
negative. The serological data using anti-Qa2 subregion sera indicates  an identical 
strain distribution  for the antigen. In contrast, TL alloantigens show no correlation 
with  Qa-2.  Therefore,  these  data  are consistent  with  the  idea  that  the  Qa-2 CTL 
determinant is identical with serologically defined Qa-2. 
A second approach used to determine whether serological and CTL determinants 
are the same is to use anti-Qa2 subregion antibodies in an attempt to block anti-Qa 
CTL activity. The data in Table V demonstrate that B6.K 1 anti-A.BY/B6.K2 effector 
cells  have their  CTL activity completely blocked when  the  B6.K2  target  cells  are 
exposed to a polyvalent anti-Qa2 subregion sera before their addition  (lines 3 and 4, 
columns A  and  B).  The same antisera has no effect in  blocking the anti-H-2 CTL 
response (line 10, column A). Monoclonal anti-Qa-2 only blocks ~50% of CTL activty 
directed against B6.K2 target cells (lines 5 and 6, column B). This partial inhibition 
is  not  because of incomplete  masking of the  Qa-2  CTL determinant  because  this 
antibody  efficiently  blocks  CTL  activity  directed  against  Qa-5-  target  cells  (see 
below).  Monoclonal  anti-Qa-2  had  no  activity in  blocking anti-H-2b-specific CTL 
(data not shown). 
Because Qa-5 defines a second CTL target antigen (see previous section), the failure 
of monoclonal  anti-Qa-2  to  completely block CTL activity  is  expected.  However, 
monoclonal  anti-Qa-5  either  alone  or  together  with  monoclonal  anti-Qa-2  has  no 
blocking activity (lines 7 and 8, column B). This result could either be the result of an 
inability of monoclonal anti-Qa-5  (which has a relatively low titer) to properly mask j.  FORMAN,  J.  TRIAL,  S.  TONKONOGY,  AND  L.  FLAHERTY 
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Fx~.  3.  Qa-5 is associated with a target antigen for anti-Qa CTL. Spleen cells, from B6.KI mice 
primed in vivo with A.BY cells were boosted in vitro with stimulator cells from BALB/c  J  (panel A) 
or B6.K2 (panel B) and tested for their cytotoxic activity against B6.K2 target ceils in the presence 
of unlabeled inhibitor  ceils from B6.K1 (*), B6.K2 (×), and BALB/cJ (O). Net release in the absence 
of inhibitor ceils was 12% for the target cells used in panel A and 29% for the target cells used in 
panel B. 
the Qa-5 CTL  determinant or possibly that a  molecule other than Qa-5 contains the 
target specificity. This issue is currently under investigation. 
The same kind of testing was  done on BALB/cJ  (Qa-5-)  target  cells to eliminate 
anti-Qa-5-associated CTL  activity. In this case, both polyvalent K1 anti-B6 and the 758  CYTOTOXIC  T  CELLS  AGAINST Qa-2 
TABLE IV 
Distribution of Serological and CTL Qa-2 Determinants in 
BIO. W  (wild) Mice 
Presence of 
Strain  CTL determi-  Qa-2  Tla 
nant  serology  genotype 
BALB/cJ  +*  +~  c~ 
BALB/cByJ  -  -  c 
B10.STC77  -  -  c' 
B 10.KPB 128  +  +  c' 
B10.KEA5  +  +  a' 
B 10.SNA70  +  +  c' 
B 10.CAA2  -  -  a' 
B 10.STA  12  +  +  a' 
BI0.GAA37  +  +  b' 
Effector cells were BALB/cByJ spleen cells obtained from mice Wimed in 
vivo with B10.D2 spleen cells. The primed cells were cultured in vitro with 
BALB/cJ splenoeytes for 5 d before testing. 
* Plus sign represents net release >t0% at E:T of 50:1. 
:~ Tested using B6.K1 anti-B6 sera. 
§ Tested  using  (B6  ×  A.CA)Fx anti-B6.Tla ~ sera  (anti-Tla 5,6) and  (B6  × 
A.Tlab)Fl anti-ASL-1 sera (anti-Tla 1,2,3,5,6). Preliminary work in L. Flah- 
erty laboratory indicates that these mice probably possess unique TL phe- 
notypes. We have therefore denoted them a' (strongly positive with anti-TL 
1, 2, 3, 5, 6 and anti-TL 5, 6), c' (reactive with anti-TL 1, 2, 3, 5, 6 only), or 
b' (unreactive with either antisera). 
monoclonal anti-Qa-2 reagent block CTL activity to an equivalent extent  (lines 14- 
17, columns A  and B). Although most of the CTL activity (75-86%) in the experiment 
presented in column A  is inhibitable by both antisera (lines 14 and  16), only ~50% of 
the activity is blocked in the experiment presented in column B  (lines 14 and  16). We 
interpret this inability to completely block lysis in the following manner. B6.K1  anti- 
A.BY/B6.K2 effector cells exert, in most experiments, a  low level of lysis against non- 
Qa2  subregion  antigens  on  BALB/c  target  cells.  Examples  of this  reactivity  are 
presented in the experiments shown  in Table III and Table V  (line  11, column  B), 
where significant lysis was detectable on BALB/cByJ targets. Because this lysis is not 
Qa2  subregion  directed,  killing against BALB/cJ  targets should not  be completely 
inhibitable with anti-Qa sera and accounts for a  result of only partial inhibition, viz., 
Table V  (lines 14-17, column B). 
Therefore, these antibody-blocking experiments define two determinants recognized 
by  anti-Qa2  subregion  effeetor  cells.  One  determinant  is  expressed  on  the  Qa-2 
molecule and can be masked by monoclonal anti-Qa-2 antibody when the target cells 
are from  BALB/cJ  mice. The same  monoclonal anti-Qa-2 antibody does not  com- 
pletely block lysis on B6.K2 target cells, although a polyvalent anti-Qa-2 reagent does. 
This indicates that there is another CTL target antigen and is in agreement with the 
results presented in the previous section, which  also show  that Qa-5  (or a  molecule 
coordinately expressed with Qa-5)  is a  target specificity. 
Even though anti-Qa-2 CTL are H-2 unrestricted, it is still possible that H-2K or 
D  play a role in controlling the specificity of the effector cells. For example, Qa-2 may 
associate on the cell membrane with H-2 in such a  way that a  determinant is formed 
that  is cross-reactive with all Qa-2 + strains. Alternatively, the H-2 molecule may be J.  FORMAN, J.  TRIAL, S.  TONKONOGY, AND L.  FLAHERTY 
TABLE V 
Ability of Anti-Qa and Anti-H-2 Sera to Block CTL Activity 
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Cells  Net release 
Line  Sera 
Effector  Target  A*  B 
1  B6.K1 anti-B6.K2:~  B6.K2  NMS§ (1/5) II  zo  33 
2  MP (1/5)  39 
3  K1 a-B6 (1/5)  1 (95)¶  0 (100) 
4  (1/10)  2 (93)  0 (100) 
5  M a-2 (1/5)  23 (41) 
6  (1/10)  19 (51) 
7  M a-5 (1/5)  38 (3) 
{M a-2 (1/10) 
8  +  a-5 (1/10)  22 (44) 
9  B10.S anti-B6.K2  NMS (1/5)  22 
10  K1 a-B6 (1/5)  22 (0) 
11  B6.K1 anti-B6.K2  BALB/cBy  0  16 
12  BALB/cJ  NMS (1/5)  16  42 
13  MP (1/5)  14  44 
14  K1 a-B6 (1/5)  4 (75)  19 (55) 
15  (1/10)  7 (56)  21 (50) 
16  M a-2 (1/5)  2 (86)  25 (43) 
17  (1/10)  7 (50)  22 (50) 
18  M a-5 (1/5)  40 (9) 
* Data in this Table are taken from three different experiments. Experiment 1 is listed under the column 
marked A, lines 1-10, E:T -- 100; experiment 2 is listed under A, lines 11-18, E:T -- 25; experiment 3 is 
listed under B, lines 1-18, E:T -- 50. 
See Table II. 
§NMS, and is control for KI  a-B6;  MP =  TEPC183  (uk)  1 mg/ml and is a  control for monoclonal 
antibody; K1 a-B6 is a polyvalent anti-Qa2 subregion antiserum; M a-2 is monoclonal anti-Qa-2; M a- 
5 is monoclonal anti-Qa-5. 
II Represents final concentration of serum or antibody in microtiter wells during CTL assay. 
(net release in presence of antisera) 
¶ The percent inhibition is 1 -  ×  100. 
(net release in presence of control serum) 
requisite for target cell lysis; e.g., after effector cell interaction with Qa-2 + target cells, 
a  secondary interaction may be induced involving H-2 molecules that permits target 
cell lysis. Accordingly, we attempted to block anti-Qa-2 CTL  activity with anti-H-2 
sera. The data in Table VI demonstrate that anti-H-2 sera block the activity of anti- 
H-2 CTL. However, the same sera are unable to block the cytotoxic potential of anti- 
Qa2  subregion effector  cells when tested  against either  B6.K2  or BALB/cJ  targets. 
Therefore, this data further confirms that anti-Qa CTL are H-2 unrestricted and that 
H-2K or D  molecules do not play an obligatory role in target  cell lysis mediated by 
CTL. 
Qa-2 ls Not Polymorphic.  The serological data suggest that there are only two Qa-2 
alleles, a  and b  (see Table VIII, alternative A). To further test if the Qa-2 CTL  gene 
is  polymorphic,  we  generated  anti-Qa-2  CTL  using  BALB/cByJ  anti-BALB/cJ 
effector  cells  and  tested  against  BALB/cJ  targets  in  the  presence  of inhibitor cells 
from Qa-2- (B6.K1) or Qa-2 ÷ strains. The latter included B6.K2 and 3 B 10.W strains. 
If Qa-2 is polymorphic, then it is likely that B 10.W strains will express this polymor- 
phism such that some of the wild strains would be unable to block all the anti-Qa-2 
CTL  activity  in  the  competition  assay.  However,  the  data  in  Fig.  4  (panel  A) 760  CYTOTOXIC  T  CELLS  AGAINST  Qa-2 
TABLE  VI 
Inability of Anti-H-2 Sera to Block Anti-Qa CTL Activity 
Cells 
Effector  Target 
Sera  Net release 
B6.K1 anti-B6,K2*  B6.K2  NMS$ (1/5)§  26.9 
(1/10)  24.4 
Anti-H-2  b (1/5)  21.6  (20) 
(1/10)  24. t  (1) 
B10.D2 anti-B10 [I  37.8 
Anti-H-2  b (1/5)  3.5 (91) 
Anti-H-2  b (1/10)  14.1 (63) 
B6.K1 anti-B6.K2  BALB/cJ  NMS (1/4)  25 
(i/8)  30 
Anti-H-2  d (1/4)  32  (-28)¶ 
(1/8)  34 (- 13) 
B6.K1 anti-BALB/cJ  NMS (1/4)  14 
(t/s)  13 
Anti-H-2  d (1/4)  3 (79) 
(1/8)  5 (62) 
* $ § ¶ See Table V for explanation. 
]] These effector cells were generated from primary cultures and are specific 
"for H-2 antigens. Anti-H-2 sera are described in Materials and Methods. 
demonstrate that all four Qa-2 + strains are able to block CTL activity when tested 
against  B6.K2 targets.  Further, when the same effector cells were tested against the 
three B10.W target cells, all four inhibitors showed similar activity in blocking anti- 
Qa-2 CTL responsiveness. Although the extent of inhibition varied somewhat against 
different targets (see panels A and C), this was not a consistent finding in two other 
experiments.  Therefore,  the  Qa-2 locus  controlling  the  CTL  determinant  is  not 
polymorphic. 
The Qa2 Subregion Does Not Restrict the Specificity of Antigen-specific CTL.  Because the 
Qa-2  molecule is structurally similar to H-2 class I  antigens and serves as a  target 
antigen  for H-2-unrestricted CTL,  it  is  possible  that  this  molecule has  a  function 
similar to H-2 in that it restricts antigen-specific CTL responses. However, the data 
in  Fig.  5  indicate  that  anti-minor  H  antigen  CTL  do  not  have  their  specificity 
restricted by the Qa-2 subregion.  Accordingly, B10.A  (H-2 a)  anti-A/J  (H-2 ~)  anti- 
minor H  antigen CTL lyse A/J and A.TL targets, as expected, because they share all 
or the D-end  of the H-2 ~ haplotype with H-2 ~, whereas A.BY (H-2 b) and A.SW (H-2 ~) 
target cells are not lysed (Fig. 5, top panel). More importantly, although all four of 
these target cells are Qa-2+,3 +, it is H-2 and not Qa that determines whether a target 
cell is sensitive to lysis.  In the reverse direction, A.BY (H-2~  anti-B10 (H-2~  CTL 
lyse B10 but not B10.A (H-2 a) target cells, even though they both express Qa-2,3 in 
common (Fig. 5, bottom panel). Therefore, the Qa2 subregion does not restrict CTL 
generated against minor H  antigens. 
Discussion 
The data in this report provide functional evidence to indicate that Qa-2 is similar 
to class I H-2 antigens. Accordingly, cytotoxic T  ceils can be generated against Qa-2 
that are H-2 unrestricted in their specificity. This was demonstrated not only by the j.  FORMAN, J.  TRIAL, S.  TONKONOGY, AND  L.  FLAHERTY  761 
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Fro.  4.  Qa-2  is not polymorphic. BALB/cByJ mice were primed with B 10.D2 cells in vivo, followed 
by boosting with BALB/cJ cells in vitro. The resultant effector cells were tested against targets in 
the presence of unlabeled inhibitor cells from B6.K1 (*), B6.K2 (X), B10.KPB128 (O), BI0.KEA5 
(I), and B10.GAA37 (+). Target  cells are B6.K2  (panel A), B10.GAA37, (panel B) BI0.KPB128 
(panel C'), and B10.KEA5  (panel D). Net release in the absence of inhibitor cells was 19% in A, 22% 
in B, 21% in (3, and 13% in D. 
ability  of  anti-Qa-2  effector  cells  to  lyse  Qa-2 +  target  cells  with  differing  H-2 
haplotypes,  including  five B10.W strains,  but  also by the fact  that  anti-Qa-2  CTL 
activity can be blocked by pretreating the target cells with a monoclonal anti-Qa-2 
antibody but not anti-H-2 sera. Therefore, in addition to H-2 class I and II antigens, 
Qa-2  serves  as  a  target  antigen  for CTL,  without  the  imposition  of a  specificity 
restriction by another locus. Similar results have been reported for the Qa-1  antigen 
(19, 22, 23). 
In addition  to functional  data,  there are remarkable similarities at the structural 
level between H-2 and Qa-2. For example, Qa-2 and H-2K/D  molecules consist of a 
40,000 to 44,000 tool wt heavy chain glycoprotein noncovalently associated with beta 
2-mieroglohulin  (I2,  13). Soloski et al. (14) compared tryptie peptides between Qa-2 
and  H-2  heavy  chains  and  noted  that  20-40%  were  homologous.  This  level  of 
homology is found when H-2K and H-2D alloantigens  are compared and has been 
interpreted  to  indicate  a  sequence  homology  of  between  75  and  90%  (24,  25). 
Therefore, these studies re-enforce the idea that H-2 and Qa-2 have similar functions. 
However,  in  spite  of the  above-mentioned  similarities,  several  differences  exist 762  CYTOTOXIC  T  CELLS  AGAINST  Qa-2 
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Fto.  5.  Qa2 does not restrict anti-minor H-antigen CTL.  B10.A animals were sensitized against 
A/J spleen cells and tested against target cells from A/J (*), A.TL (×), A.BY (©), and A.SW (+), 
top panel. A.BY animals were sensitized against BI0 spleen cells and tested against target cells from 
B|0 (*), B10.BR (+), Bi0.A (©), and B10.M (X), bottom panel. 
between Qa-2 and H-2, which are summarized in Table VII. For example, H-2K, D, 
and L (class I antigens) serve as restricting elements for antigen-specific CTL, whereas 
Qa-2 does not. In this report, we demonstrated that CTL generated against minor H 
antigens are not Qa-2-subregion restricted. Examination of previous studies designed 
to determine the specificity of anti-minor H, -viral, -tumor, and  -hapten sensitized 
CTL, also reveal that restriction is at H-2 rather than Qa2 (16, 26-28). However, data J.  FORMAN, J.  TRIAL, S. TONKONOGY,  AND  L.  FLAHERTY 
TAnLE VII 
Similarities between Qa-2 and H-2K/  D 
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Qa-2  H-2K/D 
Structure  40,000 tool wt H-chain associated  44,000  mol wt  H-chain associated 
with beta-2 microglobulin, pep-  with beta-2 microglobulin, pep- 
tide map similar to H-2K/D  tide map similar to Qa-2 
Primary in vitro CTL  -  + 
Unrestricted C:TL target  +  + 
antigen 
Restricting locus for 
antigen-specific CTL 
Polymorphism 
Tissue distribution 
-  (?)  + 
Peripheral  T  cells, T  and  B cell 
lymphoblasts, some thymocytes, 
multipotential stem cells, progen- 
itors  of  granulocytes/macro- 
phages, some NK cells 
+ 
All cells 
indicating a  lack of Qa2 restriction  needs to be interpreted  with caution because it is 
possible that there is an antigen that has not yet been tested that will be Qa2 restricted. 
Further,  H-2 restriction  may predominate  over Qa2 restriction,  so  that  even  if the 
latter potential exists, it might not be detected. 
A second difference between H-2 and Qa-2 is that primary anti-H-2 CTL responses 
can be generated, whereas anti-Qa-2 responses cannot. The simplest interpretation  of 
this data is that there is a low number of anti-Qa-2 CTL precursors that need in vivo 
priming for expansion  so that  they can then be detected  in the in vitro assay. This 
issue is addressed in detail by Keene and Forman (20). 
Based on serological data, it has been determined that Qa-2, unlike most H-2 genes, 
expresses  only a  positive  and  null  allele.  Therefore,  we used  a  different  approach, 
namely,  an  analysis of Qa-2 CTL determinants,  to further  investigate whether  this 
gene is polymorphic. This was approached by generating anti-Qa-2 CTL and testing 
for antigenic polymorphism on Qa-2  ÷ B10.W  (wild)  strains of mice.  The data  from 
CTL  competition  assays  revealed  no  detectable  differences  between  Qa-2  CTL 
determinants  on three different B 10.W strains and one standard laboratory strain.  In 
addition,  comparative peptide  maps of Qa-2 taken from several laboratory and wild 
strains  of mice  reveal  no  structural  differences  (M.  Soloski, J.  W.  Uhr,  and  E.  S. 
Vitetta, personal communication). Taken together, these data demonstrate that Qa-2 
is a  nonpolymorphic locus. 
It is likely that class I H-2 genes function by allowing for T  lymphocyte recognition 
of pathogenic microorganisms that express antigenic determinants on cell membranes. 
The polymorphism of these genes is thought to allow individual members of a species 
to mount an immune response against  antigenically  different pathogens. This inter- 
pretation  of H-2 makes  it  unlikely that Qa-2 functions in a  similar  manner because 
Qa-2 has not been demonstrated as a  restricting locus for antigen-specific CTL, nor is 
it  polymorphic.  We  favor the  possibility  that  Qa-2 and H-2 arose  from a  common 
ancestral  gene and that  Qa-2 diverged through evolution  to acquire  a  different and 
yet unknown function. 
There is a  parallel between the IEa gene in the H-2 complex and Qa-2 in that both 764  CYTOTOXIC  T  CELLS AGAINST Qa-2 
genes display relatively limited or no polymorphism, and each has a null allele (29). 
Strains with a null IE. allele presumably use the product of a duplicated gene, IA, for 
immune function (30). In a similar manner, Qa-2  b strains may have a duplicated gene 
that functions in its stead. It should also be noted that a null Qa-2 allele does not rule 
out the possible presence of a  Qa backbone molecule that is invariant in all mouse 
strains, including those that type as Qa-2-. 
In addition to the Qa-2 antigen, the Qa2 subregion controls the expression of three 
other cell surface antigenic specificities, Qa-3, Qa-4; and Qa-5. The strain distribution 
of Qa-2 and Qa-4 is identical, and both antigens have a  similar tissue distribution, 
although Qa-4 seems to be present in lesser amounts on the cell surface than Qa-2 (7, 
and unpublished data). However, this difference could be accounted for by the anti- 
Qa-4 monoclonal antibody having a lower affinity for antigen relative to anti-Qa-2. 
Therefore, because there is  insufficient evidence to consider these  determinants  as 
different, we propose that these two specificities define the same antigen, Qa-2. With 
this interpretation, the  genetic organization of this subregion can be explained by 
postulating that there are three genes. Each gene has two alleles, one encodes for a Qa 
antigen and is designated a, and the second is a null allele, b. Alternatively, there may 
be only one gene in this subregion with four alleles. Three of the alleles, a, c, and d, 
encode for Qa-2 alloantigens, whereas the fourth allele, b, is null (see Table VIII). We 
favor the former possibility because anti-Qa-2,3 CTL did not detect any antigenic 
differences between Qa-2+3  -  and Qa-2+3 + inhibitor cells in a cold target competition 
assay,  and  no structural  differences, as  determined by comparative peptide  maps, 
have been  detected  between  Qa-2  molecules isolated  from Qa-2+3 +  and  Qa-2+3 - 
strains (M. Soloski, E. S. Vitetta, and J. W. Uhr, personal communication). 
In addition to Qa-2, we found a  second Qa2 subregion-controlled target antigen 
TABLE VIII 
Interpretations of the Qa-2 Subregion 
Region 
Loci 
Alleles 
Antigens 
Region 
Loci 
Alleles 
Antigens 
Qa2 
Qa-2  Qa-3  Q,-5 
a  a  a 
b  b  b 
Qa-214]*  Qa-3  Qa-5 
Qa-2 
a 
b 
c 
d 
Qa-2" (214]') 
Null 
Qa-2  c (2141, 3) 
Qa-2" (2141, 3, 51 
Qa2 
* Qa-4 has the same strain distribution as Qa-2 and a similar tissue distribution. 
Because it is likely that Qa-2 and Qa-4 are the same antigen, we have defined 
the Qa2 subregion with this assumption. Two alternative interpretations of 
the genetic organization  of the  Qa2 subregion  are  presented. The  data 
presented in this paper favors possibility A. See text. j,  FORMAN, J.  TRIAL, S. TONKONOGY, AND  L.  FLAHERTY  765 
that  is  associated  with  Qa-5  expression.  This  was  demonstrated  in  a  cold  target 
competition assay in which anti-Qa-2,5 CTL effector activity could not be completely 
blocked with Qa-2+5 -  inhibitor cells when tested against Qa-2+5 ÷ targets. We further 
demonstrated that this result was not because of a greater level of Qa-2 expression on 
Qa-5 + cells because effector cells generated only against the Qa-2 antigen and tested 
against  Qa-2+5 ÷ targets could have their activity completely blocked with Qa-2+5 - 
inhibitor cells. On the other hand, monoelonal anti-Qa-5 antibody did not block any 
anti-Qa-2,5 effector activity. Therefore, at present we cannot determine whether the 
failure of this antibody to block is the result of an inability to mask CTL determinants 
on the Qa-5 molecule or possibly that a molecule other than Qa-5 expresses the target 
antigen. All Qa-5 + strains express both Qa-2 and H-2D  b. This suggests that anti-Qa- 
5 CTL are both H-2 and Qa-2 restricted. However, this possibility is unlikely because 
neither anti-H-2 nor anti-Qa-2 sera inhibits anti-Qa-5-assoeiated CTL activity. 
We (16) have previously suggested that H-2 may possess an enzymatic function on 
target  cells that  permits  their destruction by CTL.  Langman  (31), and  Cohn  and 
Epstein (32) have suggested that H-2K or D play a role in the formation of membrane 
channels or sites that cause cell lysis after interaction with effector cells. Accordingly, 
these postulates require an active role for H-2K/D on target cells for lysis to occur, 
irrespective of effector cell specificity. However, the data in this report indicate that 
H-2 does not play a necessary role on target cells for their CTL-mediated lysis. This 
was demonstrated not only by the fact that  anti-Qa2 CTL are H-2 unrestricted in 
their specificity, but also by the observation that anti-H-2 sera is unable to block anti- 
Qa-2 CTL activity. On the other hand, if Qa-2 has a  function similar to class I H-2 
antigens, then the above suggested functional role for H-2 may be substituted for by 
Qa-2. 
Summary 
B6.KI  mice  were  immunized  with  spleen  cells  from  B6.K2,  a  Qa2-subregion 
congenic strain. Cytotoxic T  cells were generated that recognize two target antigens 
controlled by this region. 
One of the target antigens  is Qa-2. This was demonstrated by the findings that 
pretreatment  of target  cells  with  monoclonal anti-Qa-2  antibody blocked  lysis  of 
target cells, and Qa-2 target antigens and serological determinants had a concordant 
distribution on a  panel of B10.W (wild) mice. The gene controlling the Qa-2 target 
antigen is not polymorphic because B6.K2 and three strains of Qa-2 + B10.W mice 
express the same antigens,  as determined by a  CTL cold target  competition assay. 
Anti-Qa-2  CTL  were  H-2  unrestricted  because  effector cells  lysed  Qa-2  +  targets 
irrespective of their H-2 haplotype, including five B 10.W strains,  and lysis was not 
inhibited by pretreating target cells with anti-H-2 sera. The Qa2 subregion does not 
act as a restricting locus for anti-minor-H antigen CTL. 
A second target antigen was detected that was associated with the expression of the 
Qa-5 determinant. However, CTL activity could not be blocked by pretreating target 
cells with monoclonal anti-Qa-5. Therefore, the CTL target antigen may be expressed 
on a Qa-5- molecule. Although the Qa-5 associated CTL specificity is only detected 
on H-2D  b strains, it is unlikely that CTL recognition is H-2 restricted because anti-H- 
2  b sera has no effect in blocking this reactivity. 
Qa-2 and H-2 class I antigens share a similar structure and serve as target antigens 766  CYTOTOXIC T  CELLS AGAINST Qa-2 
for unrestricted CTL. However, unlike class I H-2 genes, Qa-2 neither restricts antigen- 
specific CTL nor is polymorphie. Therefore, it is likely that Qa-2 and H-2 are derived 
from a common ancestral gene and have evolved to serve different functions. 
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